Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (81-90 of 740) with videos related to

Pageof 74
Sort By:
Blood|February 15, 2013
Optimal use of bisphosphonates in patients with multiple myelomaEvangelos Terpos, G David Roodman, Meletios A Dimopoulos
Blood|February 15, 2019
Myeloma bone disease: from biology findings to treatment approachesEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Meletios A Dimopoulos
American Journal of Hematology|February 7, 2026
Response to "Determinants of Ultra-Long-Term Survival in Multiple Myeloma: A Critical Appraisal of Foundational Assumptions and a Call for Biologically Driven Inquiry"Meletios A Dimopoulos, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis
Leukemia & Lymphoma|November 30, 2016
When to recommend a second autograft in patients with relapsed myeloma?Dimitrios C Ziogas, Evangelos Terpos, Meletios A Dimopoulos
Expert Review of Hematology|January 18, 2017
Emerging treatment approaches for myeloma-related bone diseaseMaria Gavriatopoulou, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Expert Opinion on Emerging Drugs|May 20, 2016
Emerging antibodies for the treatment of multiple myelomaFlora Zagouri, Evangelos Terpos, Efstathios Kastritis, et al.
Therapeutic Advances in Hematology|May 19, 2022
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myelomaDespina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, et al.
The New England Journal of Medicine|August 6, 2025
Daratumumab for High-Risk Smoldering Multiple Myeloma. ReplyMeletios A Dimopoulos, Peter M Voorhees, S Vincent Rajkumar
Targeted Oncology|April 4, 2009
Targeted therapies in multiple myelomaEfstathios Kastritis, Andreas Charidimou, Andreas Varkaris, et al.
Expert Opinion on Pharmacotherapy|September 21, 2016
Current treatments for renal failure due to multiple myelomaMaria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, et al.
Pageof 74

Showing results (81-90 of 740) with videos related to

Sort By:
Pageof 74
Blood|February 15, 2013
Optimal use of bisphosphonates in patients with multiple myelomaEvangelos Terpos, G David Roodman, Meletios A Dimopoulos
Blood|February 15, 2019
Myeloma bone disease: from biology findings to treatment approachesEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Meletios A Dimopoulos
American Journal of Hematology|February 7, 2026
Response to "Determinants of Ultra-Long-Term Survival in Multiple Myeloma: A Critical Appraisal of Foundational Assumptions and a Call for Biologically Driven Inquiry"Meletios A Dimopoulos, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis
Leukemia & Lymphoma|November 30, 2016
When to recommend a second autograft in patients with relapsed myeloma?Dimitrios C Ziogas, Evangelos Terpos, Meletios A Dimopoulos
Expert Review of Hematology|January 18, 2017
Emerging treatment approaches for myeloma-related bone diseaseMaria Gavriatopoulou, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Expert Opinion on Emerging Drugs|May 20, 2016
Emerging antibodies for the treatment of multiple myelomaFlora Zagouri, Evangelos Terpos, Efstathios Kastritis, et al.
Therapeutic Advances in Hematology|May 19, 2022
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myelomaDespina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, et al.
The New England Journal of Medicine|August 6, 2025
Daratumumab for High-Risk Smoldering Multiple Myeloma. ReplyMeletios A Dimopoulos, Peter M Voorhees, S Vincent Rajkumar
Targeted Oncology|April 4, 2009
Targeted therapies in multiple myelomaEfstathios Kastritis, Andreas Charidimou, Andreas Varkaris, et al.
Expert Opinion on Pharmacotherapy|September 21, 2016
Current treatments for renal failure due to multiple myelomaMaria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, et al.
Pageof 74